Page 5 - Guy Goodwin News Today

Single-dose synthetic psilocybin improves the core symptoms of treatment-resistant depression, while other frequently measured parameters only contribute noise to the outcome, phase 2 data show.

How do you know if your day spent riding an emotional rollercoaster of manic highs and depressive lows is normal or a sign of bipolar?

Could your highs and lows be the result of a mental health issue? Imy Brighty-Potts asks the experts.

It’s not unusual to experience a shift in mood, but if it seems like you spend your days riding an emotional roller coaster of ups and downs, there could be an underlying reason.

Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded.

CMPS earnings call for the period ending December 31, 2022.

Guy Goodwin of COMPASS Pathways, explores the potential of tryptamines / psilocybin therapy in treatment resistant depression.

Mental health care company COMPASS Pathways plc (NASDAQ:CMPS) has announced positive data demonstrating the potential of its proprietary synthetic...

Investegate announcements from COMPASS Pathways, COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II